Journal Flyer

Online Journal of Cardiology Research & Reports - OJCRR

ISSN: 2693-4965

Managing Editor: Catherine Ali

Contact us at:

Open Access Mini Review

Optimizing Cardiovascular and Renal Outcomes with Canagliflozin- A Focus on CANVAS and CRENDENCE Trials

Tarek Samy Abdelaziz* and Salwa Ibrahim

Department of Renal medicine, Cairo university hospitals, Egypt

Corresponding Author

Received Date: October 26, 2019;  Published Date: November 01, 2019

Abstract

Canagliflozin is one of the sodium glucose cotransporters 2 (SLGT2) inhibitors. In addition to its glucose lowering effect, it has cardiovascular and renal protective mechanisms, through decreasing blood pressure, body weight, diuresis and natriuresis. This has translated into beneficial cardiovascular and renal outcome as compared to placebo in two recent large trials. The most pronounced effects occur in patients with moderate and severe albuminuria.

Article Details
Citation

  • Tarek Samy Abdelaziz, Salwa Ibrahim. Optimizing Cardiovascular and Renal Outcomes with Canagliflozin- A Focus on CANVAS and CRENDENCE Trials. On J Cardio Res & Rep. 3(1): 2019. OJCRR.MS.ID.000552.

Signup for Newsletter
  • newsletter-subscription
© 2018 Iris Publishers LLC, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use. Creative Commons License Open Access by
Iris Publishers LLC is licensed under Creative Commons License a Creative Commons Attribution 4.0 International License. Based on a work at www.irispublishers.com. Best viewed in browser_icons browser_icons | Above IE 9.0 version | Privacy Policy
Scroll to Top